← Back to Search

Propranolol + Nicotine Patch for Smoking Addiction

Phase 4
Waitlist Available
Led By Jason A Oliver, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 4-5 hours
Awards & highlights

Study Summary

This trial looks at how a drug and nicotine patch affect the brain and behavior when exposed to smoking cues. It's a short-term experiment in humans with no quit attempt.

Who is the study for?
This trial is for English-speaking, right-handed adults aged 21-60 who have been smoking regularly for at least a year. Participants should smoke over 5 cigarettes daily and be generally healthy. Exclusions include low blood pressure, use of psychoactive drugs or certain medications, pregnancy, abnormal EKG results, severe anemia or electrolyte issues, MRI safety risks like pacemakers, vision problems uncorrectable with glasses/contacts, and significant health conditions.Check my eligibility
What is being tested?
The study tests the effects of Propranolol (a beta-blocker) and nicotine patches on smokers' reactions to cues that make them want to smoke. It's not a long-term treatment test but looks at immediate responses in controlled settings. Participants will receive either the actual drugs or placebos in various combinations.See study design
What are the potential side effects?
Propranolol can cause dizziness due to lowered blood pressure, fatigue, trouble sleeping and may worsen asthma symptoms. Nicotine patches might lead to skin irritation where applied, sleep disturbances including vivid dreams or insomnia and muscle aches.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 4-5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 4-5 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Association between Smoking Urge and Brain Activation
Brain
Oxygen saturation measurement
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Placebo Patch/Active PropranololExperimental Treatment2 Interventions
Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)
Group II: Active Patch/Placebo PropranololExperimental Treatment2 Interventions
Active Nicotine Patch (14 mg) Placebo Propranolol
Group III: Active Patch/Active PropranololExperimental Treatment2 Interventions
Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)
Group IV: Placebo Patch/Placebo PropranololPlacebo Group2 Interventions
Placebo Nicotine Patch Placebo Propranolol
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol
2010
Completed Phase 4
~1290
Nicotine Patch
2011
Completed Phase 4
~10480
Placebo Propranolol
2019
Completed Phase 1
~60
Placebo Patch
2011
Completed Phase 4
~4500

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,530 Total Patients Enrolled
4 Trials studying Tobacco Use Disorder
587 Patients Enrolled for Tobacco Use Disorder
Oklahoma State University Center for Health SciencesOTHER
35 Previous Clinical Trials
5,176 Total Patients Enrolled
Duke UniversityOTHER
2,358 Previous Clinical Trials
3,419,989 Total Patients Enrolled
28 Trials studying Tobacco Use Disorder
5,128 Patients Enrolled for Tobacco Use Disorder

Media Library

Active Patch/Active Propranolol Clinical Trial Eligibility Overview. Trial Name: NCT05587361 — Phase 4
Tobacco Use Disorder Research Study Groups: Placebo Patch/Placebo Propranolol, Placebo Patch/Active Propranolol, Active Patch/Placebo Propranolol, Active Patch/Active Propranolol
Tobacco Use Disorder Clinical Trial 2023: Active Patch/Active Propranolol Highlights & Side Effects. Trial Name: NCT05587361 — Phase 4
Active Patch/Active Propranolol 2023 Treatment Timeline for Medical Study. Trial Name: NCT05587361 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risk factors should be taken into account when utilizing Active Patch/Active Propranolol?

"Leveraging our team's expertise, Power has assigned the Active Patch/Active Propranolol treatment a score of 3 on a 1-3 scale. This rating is due to its Phase 4 trial status and regulatory approval."

Answered by AI

Are there age restrictions for participation in this clinical research?

"According to the enrollment requirements for this medical trial, those wishing to participate must be at least 21 years old and no older than 60."

Answered by AI

Are there vacancies in this medical trial for participants?

"As per clinicaltrials.gov, this trial is not actively enrolling patients at the moment. The study was first posted on November 1st 2022 and last updated October 18th of that year. Nevertheless, 148 other trials are currently seeking applicants in lieu of this one."

Answered by AI

Is it possible to volunteer for this medical trial?

"This medical trial is recruiting 80 participants between the ages of 21 and 60 who are habitual cigarette smokers. In order to be eligible for inclusion, potential patients must demonstrate general good health, have smoked a minimum of 5 cigarettes per day delivering 0.5 mg nicotine (FTC) over at least one year with no significant changes in their smoking behaviour within the past 6 months, possess an afternoon expired Carbon Monoxide concentration ≥6 ppm or morning urinary cotinine >100 ng/ml, identify 4 different locations where they typically smoke during any given week, and possess sufficient reading comprehension to understand English instructions."

Answered by AI

Who else is applying?

What site did they apply to?
Hardesty Center for Clinical Research and Neuroscience
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Beta-Adrenergic Modulation of Drug Cue Reactivity
2024. "Beta-Adrenergic Modulation of Drug Cue Reactivity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05587361.
~53 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top